<DOC>
	<DOCNO>NCT00163618</DOCNO>
	<brief_summary>The objective study ass TBE antibody persistence approximately three year administration TBE booster vaccination FSME-IMMUN 0.25 ml Junior child receive either 0.25 mL 0.5 mL TicoVac primary vaccination series Study 146A .</brief_summary>
	<brief_title>Study Investigate Seropersistence TBE Virus Antibodies Approx . 3 Years After Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR Children</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Tick-Borne</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Formaldehyde</mesh_term>
	<criteria>Male female child participate Study 146A : and/or parents/legal guardian understand nature study agree provision write informed consent available child ( accord age capacity understand ) parents/legal guardian receive complete 3immunization primary vaccination series either 0.5 ml 0.25 ml TicoVac Study 146A receive FSMEIMMUN 0.25 ml Junior first booster vaccination approximately 3 4 year third vaccination Study IMAG146A Subjects receive TBE vaccination since first TBE booster vaccination Subjects history infection , vaccination , flavivirus ( e.g . dengue fever , yellow fever and/or japanese B encephalitis virus ) since third vaccination Study 146A Subjects suffer disease ( e.g . autoimmune disease ) undergone form treatment ( e.g . systemic corticosteroid ) expect influence immunological function within 30 day first TBE booster vaccination Subjects know HIV positive ( special HIV test require purpose study ) since third vaccination Study 146A Subjects receive blood transfusion immunoglobulin within 30 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>tick-borne encephalitis</keyword>
</DOC>